Lilly's New Trio-Hormone Drug Shows Breakthrough Results

Eli Lilly's weight-loss drug retatrutide, which mimics three hormones, shows promising clinical trial results, reducing triglycerides, apoC-III, and cardiovascular risks. It surpassed current weight-loss drugs in trials. Researchers also advocate for complete revascularization in older heart attack patients for better outcomes. Additionally, blood pressure pill timing is found irrelevant.

Eli Lilly's experimental weight-loss drug, retatrutide, continues to show promising clinical trial results by mimicking three hormones, according to the company. At the European Society of Cardiology meeting in London, researchers revealed that retatrutide significantly reduced blood lipid levels and cardiovascular risks in a mid-stage trial.

At 48 weeks, retatrutide reduced triglyceride levels by 40.6% and apoC-III by 38%, surpassing current popular weight-loss drugs. Patients injected with the highest dose lost about 24% of their body weight. Additionally, there were significant improvements in liver fat among obese patients.

For heart attack patients, a study presented at the ESC meeting emphasized that older patients with multiple narrowed coronary arteries should have all arteries unclogged, not just the one causing the heart attack. Researchers found a 22% reduction in death, heart attack, or the need for another procedure at four years, advocating for a complete revascularization strategy. In another study, researchers found no significant difference between taking blood pressure medication in the morning or evening, suggesting patients take it when they are least likely to forget.